How should I evaluate and treat a patient with a prior history of pulmonary tuberculosis who now has fever, leukopenia with lymphocytic predominance, and CT chest showing fibrocalcific nodules and millimetric tree‑in‑bud nodules suggestive of superimposed infection?

Management of Suspected TB Reactivation with Endobronchial Spread

Start four-drug anti-tuberculosis therapy immediately with isoniazid, rifampin, pyrazinamide, and ethambutol without waiting for microbiologic confirmation. 1, 2

Clinical Interpretation of Imaging and Laboratory Findings

Your patient's presentation is highly consistent with active TB reactivation with endobronchial spread:

• The new tree-in-bud nodules in peribronchovascular distribution are pathognomonic for endobronchial spread of active tuberculosis, distinguishing them from the stable fibrocalcific changes representing old healed disease 2, 3
• Four days of fever with lymphocytic predominance and leukopenia (WBC 3900) strongly supports active TB infection 2, 4
• The combination of unchanged old fibrocalcific lesions with newly appearing peribronchovascular nodules is diagnostic for reactivation disease 2
• Stable fibrocalcific nodules from prior TB confer a 2.5-fold increased risk of reactivation compared to those without radiographic scarring 1, 2

Immediate Microbiologic Evaluation

Obtain at least three sputum specimens for acid-fast bacilli (AFB) smear, nucleic acid amplification testing (NAAT), and mycobacterial culture before starting treatment but do not delay therapy 1, 2:

• Collect early morning specimens if possible (12% higher sensitivity than spot specimens) 1
• Use concentrated specimens with fluorescence microscopy (18% and 10% sensitivity improvements respectively) 1
• If the patient cannot produce sputum spontaneously, perform sputum induction with hypertonic saline immediately 1, 2
• If sputum induction fails, proceed to bronchoscopy with bronchoalveolar lavage and biopsy 1, 2

Request nucleic acid amplification testing (NAAT) for same-day confirmation of Mycobacterium tuberculosis complex and rapid resistance marker detection 1

Treatment Initiation

Begin empiric four-drug therapy today with standard dosing 1, 2:

• Isoniazid
• Rifampin
• Pyrazinamide
• Ethambutol

This strong recommendation applies even with negative initial AFB smears, as approximately 17% of active pulmonary TB cases have negative cultures despite true disease 1, 2

Management Based on Culture Results

If Cultures Become Positive:

• Continue the full treatment regimen for drug-susceptible TB (typically 6 months total: 2 months intensive phase with four drugs, then 4 months continuation phase with isoniazid and rifampin) 1
• Obtain drug susceptibility testing once growth is detected, especially critical given the patient's prior TB history 1, 2

If Cultures Remain Negative:

• Reassess clinical and radiographic response at 2 months of therapy 1, 2
• If there is clinical improvement (fever resolution) or radiographic improvement (resolution of tree-in-bud nodules) with no alternative diagnosis identified, continue anti-TB therapy 1, 2
• Culture-negative TB can be treated with a shortened 4-month regimen of isoniazid plus rifampin (versus 6 months for culture-positive disease), though initial four-drug therapy should continue until cultures are finalized 1, 2

Expected Clinical Course

Most febrile TB patients become afebrile within 1 week (89%) to 2 weeks (93%) of appropriate therapy 4:

• If fever persists beyond 2 weeks, consider drug resistance, non-adherence, alternative diagnoses, or paradoxical reactions 5, 4
• Prolonged fever is associated with hypoalbuminemia, hyponatremia, and anemia 4

Tree-in-bud appearance should disappear on follow-up imaging as a marker of treatment effectiveness 3

Critical Pitfalls to Avoid

• Do not delay treatment while awaiting culture results—the combination of prior TB, new peribronchovascular nodules, and acute fever justifies immediate empiric therapy 1, 2
• Do not attribute the fever solely to old fibrocalcific changes; fever in this context signals active endobronchial spread requiring treatment 2
• Do not use tuberculin skin testing or interferon-gamma release assays to exclude active TB—these tests cannot differentiate latent from active disease 1
• Do not mistake the tree-in-bud pattern for simple bacterial pneumonia—this distribution in a patient with prior TB is TB reactivation until proven otherwise 2, 6

Differential Considerations (Lower Priority)

While nontuberculous mycobacterial infection, lymphoproliferative disease, or vasculitis could theoretically present similarly, the acute fever, classic upper-lobe distribution, prior TB history, and characteristic tree-in-bud pattern make TB reactivation overwhelmingly likely 2. Given the high pretest probability, empiric anti-TB therapy should not be postponed while evaluating these alternatives 2.